In vitro activity of Melaleuca alternifolia (tea tree) oil on filamentous fungi and toxicity to human cells

Medical Mycology

Volumn 53, Issue 3, 2015, Pages 285-294

  Homeyer, Diane C ^a   Sanchez, Carlos J ^b   Mende, Katrin ^a,c   Beckius, Miriam L ^d   Murray, Clinton K ^a   Wenke, Joseph C ^b   Akers, Kevin S ^a,b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Cell viability; Cytotoxicity; Invasive fungal infection; Melaleuca alternifolia; Tea tree oil

Indexed keywords

TEA TREE OIL; ANTIFUNGAL AGENT;

ACTINOMUCOR ELEGANS; ANIMAL TISSUE; APOPHYSOMYCES; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CELL VIABILITY; CONTROLLED STUDY; DRUG SAFETY; EXOPHIALA; FIBROBLAST; FILAMENTOUS FUNGUS; FUNGICIDAL ACTIVITY; FUSARIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; LD50; LICHTHEIMIA; MUCOR CIRCINELLOIDES; NONHUMAN; OSTEOBLAST; PIG; SYSTEMIC MYCOSIS; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ENDOTHELIUM CELL; FUNGUS; ISOLATION AND PURIFICATION; MELALEUCA; MICROBIOLOGY; MYCOSIS; WOUND INFECTION;

ANIMALS; ANTIFUNGAL AGENTS; CELL LINE; CELL SURVIVAL; ENDOTHELIAL CELLS; FIBROBLASTS; FUNGI; HUMANS; KERATINOCYTES; MELALEUCA; MYCOSES; OSTEOBLASTS; SWINE; TEA TREE OIL; WOUND INFECTION;

EID: 84956915087     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myu072     Document Type: Article

References (45)

1. Warkentien T, Rodriguez C, Lloyd B et al. Invasive mold infections following combat-related injuries. Clin Infect Dis 2012;55(11): 1441-1449.
2. Neblett Fanfair R, Benedict K, Bos J et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin,Missouri, in 2011. N Engl J Med 2012;367(23): 2214-2225.
3. Austin CL, Finley PJ, Mikkelson DR et al. Mucormycosis: A Rare Fungal Infection in Tornado Victims. J Burn Care Res 2014; 35(3): e164-e171.
4. Barsoumian A, Sanchez CJ, Mende K et al. In vitro toxicity and activity of Dakin’s solution, mafenide acetate, and amphotericin B on filamentous fungi and human cells. JOrthop Trauma 2013;27(8): 428-436.
5. Brophy JJ, Davies NW, Southwell IA et al. Gas chromotographic quality control for oil of Melaleuca terpinen-4-ol type (Australian tea tree). J Agric Food Chem 1989;37(5): 1330-1335.
6. Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol 1995;78(3): 264-269.
7. Syed TA, Qureshi ZA, Ali SM et al. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop Med Int Health 1999;4(4): 284-287.
8. Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J Fam Pract 1994;38(6): 601-605.
9. Satchell AC, Saurajen A, Bell C et al. Treatment of interdigital tinea pedis with 25% and 50% tea tree oil solution: a randomized, placebo-controlled, blinded study. Australas J Dermatol 2002;43(3): 175-178.
10. Satchell AC, Saurajen A, Bell C et al. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol 2002;47(6): 852-855.
11. Blackwood B, Thompson G, McMullan R et al. Tea tree oil (5%) body wash versus standard care (Johnson’s Baby Softwash) to prevent colonization with methicillin-resistant Staphylococcus aureus in critically ill adults: a randomized controlled trial. J Antimicrob Chemother 2013;68(5): 1193-1199.
12. Edmondson M, Newall N, Carville K et al. Uncontrolled, open-label, pilot study of tea tree (Melaleuca alternifolia) oil solution in the decolonisation of methicillinresistant Staphylococcus aureus positive wounds and its influence on wound healing. Int Wound J 2011;8(4): 375-384.
13. Hammer KA, Carson CF, Riley TV. In vitro activity of Melaleuca alternifolia (tea tree) oil against dermatophytes and other filamentous fungi. J Antimicrob Chemother 2002;50(2): 195-199.
14. Oliva B, Piccirilli E, Ceddia T et al. Antimycotic activity of Melaleuca alternifolia essential oil and its major components. Lett Appl Microbiol 2003;37(2): 185-187.
15. Barchiesi F, Silvestri C, Arzeni D et al. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. Med Mycol 2009;47(3): 321-326.
16. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 2006;19(1): 50-62.
17. Larson D, Jacob SE. Tea tree oil. Dermatitis 2012;23(1): 48-49.
18. Crawford GH, Sciacca JR, James WD. Tea tree oil: cutaneous effects of the extracted oil of Melaleuca alternifolia. Dermatitis 2004; 15(2): 59-66.
19. Hammer KA, Carson CF, Riley TV et al. A review of the toxicity of Melaleuca alternifolia (tea tree) oil. Food Chem Toxicol 2006;44(5): 616-625.
20. Greig JE CC, StuckeyMS et al. Skin sensitivity testing for tea tree oil - A report for the Rural Industries Research andDevelopment Corporation. Barton, Australia: Rural Industries Research and Development Corporation; 1999.
21. Cross SE, Russell M, Southwell I et al. Human skin penetration of the major components of Australian tea tree oil applied in its pure form and as a 20% solution in vitro. Eur J Pharm Biopharm 2008; 69(1): 214-222.
22. Woollard AC, Tatham KC, Barker S. The influence of essential oils on the process of wound healing: a review of the current evidence. J Wound Care 2007;16(6): 255-257.
23. Weintrob AC, Weisbrod AB, Dunne JR et al. Combat traumaassociated invasive fungal wound infections: epidemiology and clinical classification. Epidemiol Infect 2014: 1-11.
24. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard-Second Ed. CLSI document M38-A2. Wayne, PA: CLSI; 2008.
25. Hammer KA, Carson CF, Riley TV. Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbiol 2003;95(4): 853-860.
26. Yang Q, Phillips PL, Sampson EM et al. Development of a novel ex vivo porcine skin explant model for the assessment of mature bacterial biofilms. Wound Repair Regen 2013;21(5): 704-714.
27. Castagnoli C, Alotto D, Cambieri I et al. Evaluation of donor skin viability: fresh and cryopreserved skin using tetrazolioum salt assay. Burns 2003;29(8): 759-767.
28. Franchini M, Zanini D, Bosinelli A et al. Evaluation of cryopreserved donor skin viability: the experience of the regional tissue bank of Verona. Blood Transfus 2009;7(2): 100-105.
29. Loughlin R, Gilmore BF, McCarron PA et al. Comparison of the cidal activity of tea tree oil and terpinen-4-ol against clinical bacterial skin isolates and human fibroblast cells. Lett Appl Microbiol 2008;46(4): 428-433.
30. Söderberg TA, Johansson A, Gref R. Toxic effects of some conifer resin acids and tea tree oil on human epithelial and fibroblast cells. Toxicology 1996;107(2): 99-109.
31. Teepe RG, Koebrugge EJ, Lowik CW et al. Cytotoxic effects of topical antimicrobial and antiseptic agents on human keratinocytes in vitro. J Trauma 1993;35(1): 8-19.
32. Dryden MS, Dailly S, Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004;56(4): 283-286.
33. Sherry E, Sivananthan S, Warnke PH et al. Topical phytochemicals used to salvage the gangrenous lower limbs of type 1 diabetic patients. Diabetes Res Clin Pract 2003;62(1): 65-66.
34. Chin KB, Cordell B. The effect of tea tree oil (Melaleuca alternifolia) on wound healing using a dressing model. J Altern Complement Med 2013;19(12): 942-945.
35. Cuttle L, Kempf M, Kravchuk O et al. The efficacy of Aloe vera, tea tree oil and saliva as first aid treatment for partial thickness burn injuries. Burns 2008;34(8): 1176-1182.
36. Hart PH, Brand C, Carson CF et al. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res 2000;49(11): 619-626.
37. Glasser JS, Guymon CH, Mende K et al. Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients. Burns 2010;36(8): 1172-1184.
38. Frankenbusch K, Eifinger F, Kribs A et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol 2006;26(8): 511-514.
39. Arora R, Gupta D, Goyal J et al. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. Clin Experiment Ophthalmol 2011;39(5): 434-440.
40. Sharma N, Chacko J, Velpandian T et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Ophthalmology.2013; 120(4): 677-681.
41. Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect 2013;19(3): 210-220.
42. Hurtado-Sarrio M, Duch-Samper A, Cisneros-Lanuza A et al. Successful topical application of caspofungin in the treatment of fungal keratitis refractory to voriconazole. Arch Ophthalmol 2010; 128(7): 941-942.
43. Klein KC, Blackwood RA. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant. Pediatrics 2006;118(2): e506-508.
44. Azofra MM, Somovilla JL, Porras MC et al. Use of intralesional voriconazole for the treatment of cutaneous Scedosporium apiospermum infection. Clin Infect Dis 2010;51(2): 255-257.
45. Tammer I, Seibold M, Krause H et al. Successful topical therapy with voriconazole: pseudallescheriasis after injury. J Trauma 2007; 62(5): 1295-1297.